Coronavirus vaccine
WHO: Poorest must not be trampled in vaccines stampede
AstraZeneca and Oxford University said their prospective vaccine had proved on average 70% effective at stopping the virus after trying it on 23,000 people,...
-
AstraZeneca/Oxford say COVID-19 vaccine shows 70% efficacy
The results ranged between 62% and 90% efficacy depending on the vaccine dosage.
-
SA set for long wait for COVID-19 vaccine as roll out takes shape
Countries like the United States will ensure its citizens are catered to first, while the rest of us will have to wait a little longer to be protected from the coronavirus, which has infected more than 55 million people around the world and claimed the lives of more than 1.3 million others.
-
Pfizer/BioNTech to seek emergency use approval for coronavirus vaccine
The companies this week announced that a completed study of trials of the product showed it was 95% effective in protecting people from coronavirus infection.
-
WHO advises against remdesivir for coronavirus treatment
The United States, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.
-
Pfizer/BioNTech say results show COVID vaccine 95% effective
The new data showed the vaccine was generally well tolerated, with most side-effects short-lived and either mild or moderate.
-
Poorer nations face vaccine wait as West locks down supply
Vaccine developers Pfizer and BioNTech plan to roll out the first doses within weeks, once they receive emergency use permissions from drug agencies. They expect to have 1.3 billion doses ready next year.
-
ANALYSIS: Moderna follows Pfizer with good vaccine news – what does this mean?
Many more vaccine trial results are likely to follow in the coming months, so it’s necessary to dig deeper to find out exactly what any new results mean.
-
New vaccine breakthrough lifts global hope against pandemic
Major stock markets surged Monday in response, building on a boom sparked by the Pfizer news one week ago.
-
ANALYSIS: Pfizer COVID vaccine: promising results. What needs to happen next?
The results from the Pfizer/BioNTech COVID-19 vaccine trial are promising, but there’s a lot more we now need to confirm.
-
$500m to be pledged for COVID-19 vaccine access at Paris forum - AFP
The third edition of the Paris Peace Forum, which seeks to address governance issues with concrete projects, takes place Thursday and Friday in the French capital and is dedicated to finding ways to ease and get out of the COVID-19 pandemic.
-
Trump refuses to concede, Biden leads on COVID-19
The Trump administration is also refusing traditional cooperation with Biden's team, denying him the normal transition package that includes office space, a budget and expertise to prepare for the takeover.
-
Biden: Vaccine news gives 'hope,' but long battle ahead
Pfizer and BioNTech said that according to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.
-
Pfizer says COVID-19 vaccine 90% effective in Phase 3 trial
According to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.
-
ANALYSIS: Can we actually learn to live with the coronavirus?
Should we allow SARS-CoV-2 to spread through most of the population while shielding all the elderly and those at high risk of serious disease, thus creating some level of underlying immunity in the population?
-
UN stockpiling billion syringes for COVID-19 vaccine
Unicef, the UN Children's Fund, said it aims to get 520 million syringes in its warehouses by the end of this year, to guarantee an initial supply in countries ahead of the vaccine.
-
Coronavirus treatments: Some progress, no panacea
Very few of the drugs tested and administered so far have proven effective, a conclusion reinforced by a major WHO-backed study released on Friday.
-
YouTube to remove COVID-19 vaccine misinformation
The move is the latest by online platforms struggling to contain the spread of hoaxes and false information about the coronavirus and treatments.
-
Johnson & Johnson pauses COVID vaccine trial as participant becomes ill
The pause means the enrollment system has been closed for the 60,000-patient clinical trial while the independent patient safety committee is convened.
